Luis Miguel
Antón Aparicio
Institute Catalá Oncología
Barcelona, EspañaPublications in collaboration with researchers from Institute Catalá Oncología (1)
2014
-
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
Clinical Cancer Research, Vol. 20, Núm. 7, pp. 1925-1934